In December 2019, Civetta Therapeutics, LLC announced a $53 million Series A round financing. Civetta is a Cambridge, Massachusetts-based therapeutics company, founded to advance new medicines through small molecule targeting of beta-propeller domains with the goal of developing important drugs for cancers and other diseases.
Civetta Therapeutics, LLC
In February 2016, Deerfield invested in Ribon Therapeutics’ $24 million Series A preferred financing. Ribon is a discovery stage biotechnology company focused on a specific part of Poly Polymerases (PARPs) called monoPARP (mono ADP-ribose polymerase). These proteins are potential inhibitors to block cancer cells’ fundamental ability to survive under stress.